The Pathology Research Shared Resource (PRC) provides histological and related tissue-based services across the enterprise to Mayo Clinic Cancer Center (MCCC) members at Mayo Clinic in Rochester, MN (MCR), at Mayo Clinic in Arizona (MCA), and at Mayo Clinic in Florida (MCF). PRC works with site based resources to standardize practices across the enterprise. The services include preparation of histology slides for microscopy, tissue microarray construction, immunostaining, digital image capture and analysis, and preparation of tissues for subsequent nucleic acid or protein extraction. A team of cytotechnologists assist with morphologic interpretation of slides, choosing slides and blocks for tissue microarrays, and analysis of microscopic images. PRC provides these services to research and clinical investigators at an affordable cost with reasonable turnaround times. The majority of the services are performed using clinical diagnostic tissues that are formalin fixed and paraffin embedded, allowing MCCC members to take advantage of the wealth of clinical materials for biomarker discovery and validation. PRC also performs services on fresh tissues, animal tissues, and tissue-cultured cells to facilitate translation of basic biology to clinical relevance. PRC functions within a College of American Pathologists (CAP)-accredited quality system to provide consistent services performed according to laboratory standard operating procedures. The services provided by PRC have been vital to MCCC research at Mayo Clinic, providing members with state of the art services that would be difficult to maintain in the laboratories of individual investigators. In addition, many investigators who use PRC are epidemiologists and bioinformaticians in the MCCC Genetic Epidemiology & Risk Assessment Program (GERA), who may not have laboratory space of their own.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
5P30CA015083-47
Application #
10113594
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-04-25
Project End
2024-02-29
Budget Start
2021-03-01
Budget End
2022-02-28
Support Year
47
Fiscal Year
2021
Total Cost
Indirect Cost
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Jahanseir, Khadijeh; Xing, Deyin; Greipp, Patricia T et al. (2018) PDGFB Rearrangements in Dermatofibrosarcoma Protuberans of the Vulva: A Study of 11 Cases Including Myxoid and Fibrosarcomatous Variants. Int J Gynecol Pathol 37:537-546
Painter, Jodie N; O'Mara, Tracy A; Morris, Andrew P et al. (2018) Genetic overlap between endometriosis and endometrial cancer: evidence from cross-disease genetic correlation and GWAS meta-analyses. Cancer Med 7:1978-1987
Yu, Jia; Qin, Bo; Moyer, Ann M et al. (2018) DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. J Clin Invest 128:2376-2388
Sugihara, Takaaki; Werneburg, Nathan W; Hernandez, Matthew C et al. (2018) YAP Tyrosine Phosphorylation and Nuclear Localization in Cholangiocarcinoma Cells Are Regulated by LCK and Independent of LATS Activity. Mol Cancer Res 16:1556-1567
Natanzon, Yanina; Goode, Ellen L; Cunningham, Julie M (2018) Epigenetics in ovarian cancer. Semin Cancer Biol 51:160-169
Kleinstern, Geffen; Camp, Nicola J; Goldin, Lynn R et al. (2018) Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Blood 131:2541-2551
Liu, Gang; Mukherjee, Bhramar; Lee, Seunggeun et al. (2018) Robust Tests for Additive Gene-Environment Interaction in Case-Control Studies Using Gene-Environment Independence. Am J Epidemiol 187:366-377
Ong, Jue-Sheng; Hwang, Liang-Dar; Cuellar-Partida, Gabriel et al. (2018) Assessment of moderate coffee consumption and risk of epithelial ovarian cancer: a Mendelian randomization study. Int J Epidemiol 47:450-459
Kumar, Shaji K; Buadi, Francis K; LaPlant, Betsy et al. (2018) Phase 1/2 trial of ixazomib, cyclophosphamide and dexamethasone in patients with previously untreated symptomatic multiple myeloma. Blood Cancer J 8:70
Schafer, Eric S; Rau, Rachel E; Berg, Stacey et al. (2018) A phase 1 study of eribulin mesylate (E7389), a novel microtubule-targeting chemotherapeutic agent, in children with refractory or recurrent solid tumors: A Children's Oncology Group Phase 1 Consortium study (ADVL1314). Pediatr Blood Cancer 65:e27066

Showing the most recent 10 out of 1129 publications